VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

PHR.US

24.82

-5.12%↓

Search

Medtronic PLC

Gesloten

SectorGezondheidszorg

87.86 -1.21

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

87.65

Max

89.31

Belangrijke statistieken

By Trading Economics

Inkomsten

32M

1.3B

Verkoop

-111M

8.3B

K/W

Sectorgemiddelde

27.396

63.778

EPS

1.39

Dividendrendement

3.12

Winstmarge

15.798

Werknemers

95,000

EBITDA

-40M

2.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+8.49% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.12%

2.39%

Volgende Winsten

22 mei 2025

Volgende dividenddatum

11 apr 2025

Volgende Ex Dividend datum

27 jun 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-5.4B

115B

Vorige openingsprijs

89.07

Vorige sluitingsprijs

87.86

Nieuwssentiment

By Acuity

30%

70%

94 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Medtronic PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 feb 2025, 12:24 UTC

Winsten

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

19 nov 2024, 12:27 UTC

Winsten

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

27 feb 2025, 10:30 UTC

Top Nieuws

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 feb 2025, 11:47 UTC

Winsten

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 feb 2025, 11:46 UTC

Winsten

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic 3Q Adj EPS $1.39 >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic 3Q Net $1.29B >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic 3Q Diabetes Rev $694M >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic 3Q Organic Revenue Up 4.1% >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic 3Q EPS $1.01 >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

18 feb 2025, 11:45 UTC

Winsten

Medtronic 3Q Sales $8.29B >MDT

18 feb 2025, 10:01 UTC

Winsten
Populaire aandelen

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

21 jan 2025, 19:15 UTC

Top Nieuws

Medtronic Hires CFO From Renault -- Update

21 jan 2025, 12:17 UTC

Top Nieuws

Medtronic Hires CFO From Renault

19 nov 2024, 12:12 UTC

Winsten

Medtronic Narrows FY Guidance as 2Q Tops Views

19 nov 2024, 11:46 UTC

Winsten

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

19 nov 2024, 11:46 UTC

Winsten

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

19 nov 2024, 11:45 UTC

Winsten

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

19 nov 2024, 11:45 UTC

Winsten

Medtronic 2Q Adj EPS $1.26 >MDT

19 nov 2024, 11:45 UTC

Winsten

Medtronic 2Q Diabetes Rev $686M >MDT

19 nov 2024, 11:45 UTC

Winsten

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

19 nov 2024, 11:45 UTC

Winsten

Medtronic 2Q Net $1.27B >MDT

19 nov 2024, 11:45 UTC

Winsten

Medtronic 2Q Organic Revenue Up 5.0% >MDT

19 nov 2024, 11:45 UTC

Winsten

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

19 nov 2024, 11:45 UTC

Winsten

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

19 nov 2024, 11:45 UTC

Winsten

Medtronic 2Q Sales $8.4B >MDT

Peer Vergelijking

Prijswijziging

Medtronic PLC Prognose

Koersdoel

By TipRanks

8.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 96.4 USD  8.49%

Hoogste 109 USD

Laagste 85 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Medtronic PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

19 ratings

9

Buy

9

Hold

1

Sell

Technische score

By Trading Central

88.02 / 90.29Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

94 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.